

List of Figures

Sr. No:	Figure No.	Figure title	Page No.
1	1.1	Various functions and clinical utility of saliva in oral cancer	2
2	1.2	The hypothesized pathway for release of glycoproteins in circulation and correlation with associated molecular events	4
3	1.3	Hypothesis of the study	6
4	2.1	Anatomy of oral cavity	8
5	2.2	Incidence and 5-year prevalence of lip and oral cavity. Blue indicated 5-year prevalence, red indicates incidence.	9
6	2.3	Estimated 5-year prevalent cancer cases (adult population) in India-both sexes	9
7	2.4	Age standardized oral cavity incidence rates by sex and world area.	10
8	2.5	Top cancers in India in both sexes	11
9	2.6	Sequential changes in oral cancer progression	14
10	2.7	Glycosylation, the most abundant post-translational modifications of proteins	19
11	2.8	Schematic illustration of carbohydrate heterogeneity found on cell surface glycoproteins and glycolipids	19
12	2.9	Sialylation alterations in cancer	21
13	2.10	Structure of sialic acid	23
14	2.11	Synthesis of various tumor antigens by different types of transferases	28
15	2.12	Structures of the MMPs	33
16	2.13	Activation of MMPs	33
17	2.14	E-cadherin intercellular adhesion and cytoskeleton	36
18	2.15	Pathway for c-Jun activation	38
19	2.16	The EGFR family receptors and ligands	39
20	4.1	Principle of HABA assay	56
21	4.2	Principle of Sialyltransferase assay (solid phase assay)	59
22	4.3	Principle of Western blot	69
23	4.4	Electro-transfer of proteins from gel to membrane using semi dry method	71
24	5.1	Representative glycoprotein electrophoretic pattern	76
25	5.2	Comparison of 192 kDa, 170 kDa, 116 kDa and 44 kDa glycoprotein between controls, patients with OPC and oral cancer patients	77
26	5.3	(a) Glycoprotein electrophoretic pattern showing 230 kDa (b) Expression of 230 kDa glycoprotein in TH controls, patients with OPC and oral cancer patients	77
27	5.4	Expression of 192 kDa, 170 kDa, 116 kDa, and 44 kDa glycoproteins in TH and TNH controls and oral cancer patients	78
28	5.5	Comparison of 192 kDa, 170 kDa, 116 kDa and 44 kDa glycoprotein expression levels between controls, metastatic and non-metastatic groups.	79

29	5.6	ROC curve to assess the discriminatory efficacy of 192 kDa, 170 kDa, 116 kDa, and 44 kDa glycoproteins between (a) Controls vs. Oral cancer patients, (b) Controls vs. patients with OPC and (c) patients with OPC vs. Oral cancer patients.	80
30	5.7	In-gel digestion and further characterization of altered 230 kDa band	81
31	5.8	Standard curve for (a) protein estimation by Folin Lowry's method (b) TSA determination by TBA method	83
32	5.9	Comparison of serum and salivary TSA/TP ratio between controls, patients with OPC and oral cancer patients	84
33	5.10	(a) Serum TSA/TP ratio in PT, CR and NR; (b) Salivary TSA/TP ratio in PT, CR and NR	87
34	5.11	Kaplan Meir's survival analysis for (a) serum and (b) salivary TSA/TP ratio	88
35	5.12	Standard curve for sialidase activity	89
36	5.13	(a) Serum sialidase activity (b) Salivary sialidase activity in controls, patients with OPC and oral cancer patients	90
37	5.14	(a) Levels of serum sialidase activity in PT, CR and NR. (b) Levels of salivary sialidase activity in PT, CR and NR.	92
38	5.15	Representative pattern of (a) Serum α -2,6 sialoproteins and (b) salivary α -2,6 sialoproteins (c) Serum α -2,3 sialoproteins and (d) salivary α -2,3 sialoproteins (e) Serum and (f) salivary expression of α -2,3 and α -2,6 sialoproteins in controls, patients with OPC and oral cancer patients	93,94
39	5.16	(a) Levels of serum and (b) salivary α -2,6 and α -2,3 sialoproteins in PT, CR and NR	96
40	5.17	Standard curve for ST activity using p-Nitro phenol as standard	98
41	5.18	Comparison of (a) Serum α -2,6 ST (b) Salivary α -2,6 ST (c) Serum α -2,3 ST (d) Salivary α -2,3 ST between controls, patients with OPC and oral cancer patients	98,99
42	5.19	(a) Levels of serum α -2,3 and α -2,6 ST in PT, CR and NR and (b) salivary α -2,3 and α -2,6 ST in PT, CR and NR	101
43	5.20	Representative pattern of fucoproteins from (a) serum and (b) Bar chart representing 44 kDa fucoproteins in controls, Patients with OPC and oral cancer patients (c) Representative Salivary fucoprotein profile (d) Salivary fucoprotein levels in control, patients with OPC, and oral cancer patients.	105,106
44	5.21	Levels of (a) serum and (b) salivary fucoproteins in early and advanced disease	106
45	5.22	(a) Levels of serum fucoproteins and (b) salivary fucoproteins in PT, CR and NR	108
46	5.23	Standard curve for α -L-fucosidase activity using p-Nitrophenol as standard	108
47	5.24	(a) Serum and (b) salivary α -L-fucosidase activity in controls, patients with OPC and oral cancer patients	109
48	5.25	Levels of (a) serum α -L-fucosidase activity in PT, CR and NR (b) salivary α -L-fucosidase activity in PT, CR and NR.	112
49	5.26	Kaplan Meir's survival analysis of (a) serum and (b) salivary	113

		α -L-fucosidase activity	
50	5.27	(a) Representative pattern of <i>ST3GAL1</i> expression in paired malignant and adjacent normal tissues (b) Graphical representation of mean expression of <i>ST3GAL1</i> in paired malignant and adjacent normal tissues	115
51	5.28	(a) Representative pattern of <i>FUT3</i> , <i>FUT5</i> expression in paired malignant and adjacent normal tissues (b) Representative pattern of <i>FUT6</i> expression in paired malignant and adjacent normal tissues (c) Comparison of <i>FUT3</i> , <i>FUT5</i> and <i>FUT6</i> mRNA levels in paired adjacent normal and oral cancer tissues	116,117
52	5.29	Kaplan-Meier survival analysis of <i>FUT3</i> , <i>FUT5</i> , <i>FUT6</i> and <i>ST3GAL1</i> transcripts	118
53	5.30	Comparison of <i>ST3GAL1</i> , <i>FUT3</i> , <i>FUT5</i> and <i>FUT6</i> mRNA expression levels in non-metastatic and metastatic oral cancer tissues	119
54	5.31	Comparison of <i>ST3GAL1</i> , <i>FUT3</i> , <i>FUT5</i> and <i>FUT6</i> mRNA expression levels in oral cancer tissues with early and advanced disease	120
55	5.32	(a) Representative pattern of gelatin zymography from plasma. (b) Comparison of plasma pro MMP-2, active MMP-2, pro MMP-9, active MMP-9 between controls, patients with OPC and oral cancer patients (c) Comparison of total MMP-2 and total MMP-9 between controls, patients with OPC and oral cancer patients.	123
56	5.33	Levels of different forms of MMPs in early and advanced stage of disease	125
57	5.34	Representative pattern of gelatin zymogram from saliva	129
58	5.35	Expression of pro MMP-9, active MMP-9 and truncated 42 kDa MMP in controls, patients with OPC and oral cancer patients	129
59	5.36	Expression of pro MMP-9, active MMP-9 and truncated 42 kDa MMP in early and advanced stage of disease	130
60	5.37	Expression of pro MMP-9, active MMP-9 and truncated 42 kDa MMP in patients with LN metastasis and without LN metastasis.	131
61	5.38	(a) Representative pattern of truncated 97 kDa E-cadherin protein in adjacent normal and malignant tissues (b) Graphical representation of truncated E-cadherin expression in paired adjacent normal and malignant tissues	133
62	5.39	(a) E-cadherin protein in early and advanced stage of disease (b) Levels of truncated E-cadherin protein in non-infiltrating and infiltrating tumors (c) Levels of truncated E-cadherin protein in non-metastatic and metastatic tumors	134
63	5.40	(a) Representative pattern of <i>ECAD</i> mRNA expression in paired malignant and adjacent normal tissues (b) Graphical representation of <i>ECAD</i> mRNA expression in paired adjacent normal and malignant tissues.	134
64	5.41	(a) Graphical representation of <i>ECAD</i> mRNA expression in infiltrating and non-infiltrating tumors (b)	135

		<i>ECAD</i> mRNA expression in well, moderate and poorly differentiated tumors.	
65	5.42	Overall Survival analysis of (a) truncated E-cadherin protein and (b) <i>ECAD</i> mRNA	136
66	5.43	(a) Representative pattern of <i>CJUN</i> mRNA expression in paired malignant and adjacent normal tissues (b) Graphical representation of <i>CJUN</i> mRNA levels in paired malignant and adjacent normal tissues of oral cancer patients	137
67	5.44	<i>CJUN</i> mRNA expression in early and advanced stage of disease	138
68	5.45	(a) Representative pattern of c-Jun protein and β -actin in adjacent normal and malignant tissues (b) c-Jun protein expression in malignant and adjacent normal tissues	138
69	5.46	Kaplan Meir's survival analysis of (a) <i>CJUN</i> mRNA and (b) c-Jun protein with ROC cut-off	139
70	5.47	Standard graph for pEGFR expression by ELISA	140
71	5.48	Comparison of pEGFR expression in adjacent normal and malignant tissues	140
72	5.49	ROC curve analysis of pEGFR expression to distinguish adjacent normal and malignant tissues	141
73	5.50	(a) pEGFR expression in early and advanced stage of disease (b) Levels of pEGFR expression in metastatic and non-metastatic tumors	142
74	5.51	Overall Survival analysis of pEGFR expression	142
75	6.1	Role of glycosylation, pEGFR, E-cadherin, MMPs and c-Jun in oral cancer progression	175
76	7.1	Schematic representation of the study outcome	184